PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies ...

Taking the mat is Judo Bio, an up-and-coming biotech armed with $100 million to develop oligonucleotide medicines targeting ...

ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will present preclinical data for its proprietary Axiomer™ ...

Avidity Biosciences, Inc. surges on positive developments in AOCs for muscular disorders, strategic partnerships, and ...

The FDA has granted Fast Track designation to zilganersen for the treatment of Alexander disease, a rare type of leukodystrophy.

Newly launched Judo Bio aims to develop ligand-siRNA conjugates through its Selectively Targeting RNA Into KidnEy (STRIKE) ...

A new RNAi biotech is breaking ground with $135 million and John Maraganore, Ph.D., holding the key to the city. | A new RNAi ...

Judo Bio, a biotechnology company pioneering oligonucleotide medicines delivered to the kidney, today announced the presentation of preclinical data that demonstrate the use of megalin receptors for ...

A study led by researchers of the Institute of Biomedicine of the University of Barcelona (IBUB) has developed a new ...

Avidity Biosciences excels in antibody oligonucleotide conjugates with its stock tripling in the past year due to innovative ...

The venture capital firm Atlas Venture is launching a start-up that aims to develop antisense oligonucleotides for a ...

Moreover, CBS reported that Hurricane Helene is projected to be one of the most expensive storms in U.S. history, with ...